Green Square Capital LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 277.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 186,416 shares of the biopharmaceutical company’s stock after buying an additional 137,026 shares during the period. Pfizer comprises 1.1% of Green Square Capital LLC’s investment portfolio, making the stock its 26th largest position. Green Square Capital LLC’s holdings in Pfizer were worth $6,763,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. FCG Advisors LLC raised its holdings in shares of Pfizer by 43.9% in the first quarter. FCG Advisors LLC now owns 13,125 shares of the biopharmaceutical company’s stock valued at $466,000 after buying an additional 4,007 shares during the last quarter. Claraphi Advisory Network LLC raised its holdings in shares of Pfizer by 26.0% in the first quarter. Claraphi Advisory Network LLC now owns 22,695 shares of the biopharmaceutical company’s stock valued at $805,000 after buying an additional 4,676 shares during the last quarter. Asset Management One Co. Ltd. raised its holdings in shares of Pfizer by 2.2% in the first quarter. Asset Management One Co. Ltd. now owns 9,836,917 shares of the biopharmaceutical company’s stock valued at $349,113,000 after buying an additional 214,474 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Pfizer by 1.0% in the first quarter. Principal Financial Group Inc. now owns 15,135,014 shares of the biopharmaceutical company’s stock valued at $537,141,000 after buying an additional 149,146 shares during the last quarter. Finally, CT Mason raised its holdings in shares of Pfizer by 26.8% in the first quarter. CT Mason now owns 107,654 shares of the biopharmaceutical company’s stock valued at $3,821,000 after buying an additional 22,734 shares during the last quarter. 69.42% of the stock is currently owned by institutional investors.
In other news, major shareholder Pfizer Inc purchased 55,556 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The stock was purchased at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the acquisition, the insider now directly owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company’s stock.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.03. The firm had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.67 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 3 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Friday, November 9th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 3.10%. Pfizer’s dividend payout ratio is currently 51.32%.
A number of equities research analysts have recently commented on PFE shares. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Thursday, October 4th. Morgan Stanley set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, August 29th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a report on Tuesday, October 30th. Independent Research set a $48.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Thursday, October 4th. Finally, Credit Suisse Group set a $40.00 target price on shares of Pfizer and gave the company a “hold” rating in a report on Thursday, September 6th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $43.27.
COPYRIGHT VIOLATION WARNING: “Green Square Capital LLC Increases Position in Pfizer Inc. (PFE)” was published by BBNS and is the sole property of of BBNS. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://baseballnewssource.com/2018/12/08/green-square-capital-llc-increases-position-in-pfizer-inc-pfe/3063915.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: How analysts view the yield curve
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.